LEADER 01367nam  2200361Ia 450 
001 9910699376703321
005 20230902162243.0
035   $a(CKB)5470000002402147
035   $a(OCoLC)500848557
035   $a(EXLCZ)995470000002402147
100   $a20100119d2005      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $enoncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms : recommended prescribing information for heatlh care providers and patient labeling
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2005]
215   $a1 online resource (25 pages)
300   $a"Draft guidance."
300   $a"Labeling."
300   $a"Revision 4."
300   $a"November 2005."
517   $aGuidance for industry 
606   $aMenopause$xHormone therapy$xLabeling$zUnited States
615  0$aMenopause$xHormone therapy$xLabeling
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699376703321
996   $aGuidance for industry$93434577
997   $aUNINA